All News

Found 809 articles

• Telo Genomics Engages Key Opinion Leader to Form and Chair Myeloma Advisory Board

  10/18/2022

  Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has recently engaged Richard A. Bender MD, FACP, a veteran multiple myeloma ("MM") clinician, key opinion leader and medical diagnostics expert to establish and chair TELO's MM clinical advisory board (the "Advisory Board").

• Optellum, AI Lung Cancer Diagnosis Innovator, Secures $14M Series A Funding to Accelerate Expansion

  9/27/2022

  Optellum, an Oxford-based medtech company that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

• Breast Cancer Liquid Biopsy Market Size, Share, Trends, Report 2022-2030

  9/26/2022

  The global breast cancer liquid biopsy market size was estimated at USD 87.71 million in 2021 and it is expected to hit around USD 368.75 million by 2030 with a moderate CAGR of 17.3% from 2022 to 2030.

• Hedera Dx raises €14 million in seed funding to accelerate global adoption of liquid biopsies

  9/22/2022

  Liquid biopsy cancer testing is one of the most transformational innovations in healthcare for the next decade, directly unlocking better outcomes for patients

• Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study

  9/14/2022

  Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that the initial clinical validation stage of its ongoing clinical study for smoldering multiple myeloma ("SMM"), in collaboration with the Mayo Clinic, has completed review and analysis of its first cohort, consisting of 187 patients and has exceeded its targeted endpoints.

• UPDATE -- SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology

  9/13/2022

  SeqLL Inc. announced a new study demonstrating early cancer detection using SeqLL’s single-molecule technology was published in the peer-reviewed journal Nature Biotechnology.

• Duplex Sequencing Market, 2031 | Application of Duplex Sequencing in DNA Liquid Biopsies for the Diagnostic Procedure

  9/13/2022

  Duplex Sequencing is a commonly used technique to improve DNA sequencing accuracy.

• New Findings from Universal DX: Through a Simple Blood Test, Our Body’s Gut Bacteria Can Help Detect Early-Stage Colorectal Cancer

  9/12/2022

  Universal Diagnostics (Universal DX), a bioinformatics and multi-omics company on a mission to transform cancer into a curable disease, today announced the results of a proof of principle study demonstrating that the analysis of microbiome signatures in plasma can assist in early detection of colorectal cancer.

• SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology

  9/12/2022

  SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced a new study demonstrating early cancer detection using SeqLL’s single-molecule technology was published in the peer-reviewed journal Nature Biotechnology.

• Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

  9/9/2022

  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the introduction of GuardantINFINITY™, a next-generation liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development.

• Telo Genomics Completes Processing of Multiple Myeloma Drug Resistance Patient Samples

  8/17/2022

• Cancer Tumor Profiling Market Size to Reach USD 20.69 Billion by 2027, According to Latest Study by Emergen Research

  8/8/2022

  The Cancer Tumor Profiling Market is expected to reach USD 31.99 Billion by 2027, according to a new report by Emergen Research.

• Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer

  8/5/2022

  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests and real-world data will be presented at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022), hosted by the International Association for the Study of Lung Cancer, August 6-9 in Vienna, Austria.

• Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple Myeloma

  7/13/2022

  MM is a highly challenging and deadly blood cancer that forms in plasma cells, a type of white blood cell.

• Mercy BioAnalytics Appoints Dawn Mattoon, PhD, as Chief Operating Officer

  7/11/2022

  Mercy BioAnalytics , Inc. , a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the appointment of experienced biotechnology executive, Dawn Mattoon, PhD, as Chief Operating Officer, effective today.

• MicroRNA Market: Increasing Number of Diseases to Drive the Global Market

  7/7/2022

  Wilmington, Delaware, United States, Transparency Market Research Inc.: The global microRNA market is projected to witness notable growth during the forecast period set between 2021 and 2031.

• Next Generation DNA Sequencing (NGS) Market to reach USD 40.42 billion by 2029 and CAGR of 20% during the forecast period of 2022 to 2029 | Size, Share, Development, Growth and Demand

  7/7/2022

  Data Bridge Market Research, in its repository of market research reports, have recently added a report on the Next Generation DNA Sequencing (NGS) Market which emphasizes on the latest trends, key opportunities, drivers, and the challenges associated with the growth of the market during the forecast period of 2022 to 2029.

• Telo Genomics Completes Processing and Analysis of Smoldering Multiple Myeloma Patient Samples

  7/6/2022

  In January 2020, TELO entered into a collaboration agreement with the Mayo Clinic to conduct clinical studies targeting the development of two clinical prognostic tests for MM including TELO's lead product to identify high-risk SMM patients.

• U.S. Cancer Biopsy Market Size to Hit US$ 18.58 Billion by 2030

  6/28/2022

  The U.S. Cancer Biopsy market size was valued at US$ 7.56 billion in 2021 and is expected to hit US$ 18.58 billion by 2030, growing at a compound annual growth rate (CAGR) of 13.0% from 2022 to 2030.

• GENOMILL APPOINTS FORMER FOUNDATION MEDICINE EXECUTIVE AND PLANS TO PRESENT UNMATCHED DATA AT PMWC

  6/27/2022

  SEMINAL PRESENTATION OF FIRST ANALYTICAL VALIDATION DATA SCHEDULED FOR JUNE 30.